Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03739827 · ClinicalTrials.gov registry record

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

A clinical trial of Solid Tumor and Pediatric Solid Tumor, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
10,000
Enrollment target
3
Study locations

NCT03739827: Recruiting study of Solid Tumor and Pediatric Solid Tumor, sponsored by National Cancer Institute (NCI).

NCT03739827 is a study of Solid Tumor and Pediatric Solid Tumor that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 10,000 participants, above the 171-participant average among 196 other Solid Tumor trials with a reported enrollment target (5748% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03739827, a study of Solid Tumor and Pediatric Solid Tumor, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
10,000 participants
Enrollment target
3
Study locations

Study Summary

Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order to learn more about how these tumors develop. The information obtained from this study may lead to improved screening, preventive guidelines, and treatments. Objective: To better understand rare cancers and hereditary cancer syndromes. Eligibility: People who have a rare tumor, a family history of a rare tumor, a hereditary cancer syndrome, or a mutation that leads to rare tumors. Design: Participants will be screened with questions about their medical history and/or that of their family members. They will give a saliva sample. Participants who have a tumor will have their medical records and tests reviewed. They will answer questions about their wellbeing and needs. They may provide a tumor tissue sample. Participants may also have: * Physical exam * Clinical photography * Blood, urine, saliva, and stool samples taken * Consultation with specialists * A scan that produces a picture of the body. Either one that uses a small amount of radiation, or one that uses a magnetic field. * Genetic testing/genetic counseling. Participants will be contacted once a year. They will answer updated questions about their medical and family history. Participants will be asked to contact the study team if there are changes in their tumors. Participants may be invited to join focus groups for people with the same diagnosis of rare tumors. Participants may be invited to participate in other NIH protocols. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* RARE TUMOR LIST: 1. Acinar cell carcinoma of the pancreas 2. Adamantinoma 3. Adenosqaumous carcinoma of the pancr

Primary Outcome

To comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum (e.g. disease course and survival)

Conditions Studied

Solid Tumor Pediatric Solid Tumor Refractory Solid Tumors Malignant Solid Tumors Other Neoplasms Solid Tumors

Study Locations (3)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Oregon

  • Oregon Health and Science University - Portland

Texas

  • Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2019-01-28
Est. Completion 2032-03-31
National Cancer Institute (NCI)

3,257 total trials

What NCT03739827 shows while recruiting

NCT03739827 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 171-participant average among 196 other Solid Tumor trials with a reported enrollment target (5748% higher).

The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 0 interventions.

NCT03739827 reports a single indexed study location in Maryland, Oregon, Texas.

Frequently Asked Questions

What is clinical trial NCT03739827 about?

NCT03739827 is a clinical study titled "Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors". Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order t...

What is the current status of trial NCT03739827?

This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2019-01-28. Estimated completion is 2032-03-31.

What conditions does trial NCT03739827 study?

This clinical trial studies the following conditions: Solid Tumor, Pediatric Solid Tumor, Refractory Solid Tumors, Malignant Solid Tumors, Other Neoplasms Solid Tumors.

Who is sponsoring clinical trial NCT03739827?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03739827 being conducted?

This trial has 3 study locations across Maryland, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03739827's enrollment target sits among peer trials

10,000 1st of 196 higher than 196 of 196 other Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00160771 · 10,000 participants

    Biomechanics/Motion Analysis Laboratory Data Bank

  • NCT00896935 · 10,000 participants

    Arizona Cancer Center Biospecimen Repository

  • NCT00898235 · 10,000 participants

    Collection of Samples and Clinical Data From Patients With Amyloid Diseases

  • NCT00992303 · 10,000 participants

    Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03739827

Source: ClinicalTrials.gov NCT03739827, the US trial registry maintained by the National Library of Medicine. NCT03739827 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.